AWARD
A -- BCX4430 NDA Enabling CMC and Non-Clinical Toxicology Studies
- Notice Date
- 3/31/2015
- Notice Type
- Award Notice
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, Office of the Secretary, Acquisitions Management, Contracts, & Grants (AMCG), Office of the Assistant Secretary for Preparedness & Response (ASPR), Department of Health and Human Services, 330 Independence Ave. SW, G640, Washington, District of Columbia, 20201, United States
- ZIP Code
- 20201
- Point of Contact
- Thomas P. Hastings, Phone: 5712212978
- E-Mail Address
-
phil.hastings@hhs.gov
(phil.hastings@hhs.gov)
- Small Business Set-Aside
- N/A
- Award Number
- HHSO100201500007C
- Award Date
- 3/31/2015
- Awardee
- BioCryst Pharmaceuticals, Inc., 4505 Emperor Blvd, Suite 200<br />, Durham, North Carolina 27703, United States
- Award Amount
- $12,133,606
- Description
- BCX4430, an inhibitor of viral RNA - dependent RNA polymerase (RdRp), is the lead compound in BioCryst's broad spectrum antiviral program to meet the need for an effective and broad-spectrum parental direct-acting antiviral medical countermeasure (MCM). The proposed activity takes into account the Ebola virus diease (EVD) outbreak in West Africa while advancing the development of BCX4430 toward an NDA filing.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/OOS/OASPHEP/Awards/HHSO100201500007C.html)
- Record
- SN03685073-W 20150402/150401000006-fe6ad472c84d2b3c6df2960cd9f73ebd (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |